Sec. 204. Reauthorization; reporting requirement
148 words·~1 min read·
/bill/117/s/4535/is/section-204·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Section 738A(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–1(a) ) is amended— by striking fiscal year 2018 each place it appears and inserting fiscal year 2023 ; by striking Medical Device User Fee Amendments of 2017 each place it appears and inserting Medical Device User Fee Amendments of 2022 ; in paragraph (1)— in subparagraph (A), by redesignating the second clause
(iv)(relating to analysis) as clause (v); and in subparagraph (A)(iv) (relating to rationale for MDUFA program changes), by striking fiscal year 2020 and inserting fiscal year 2023 ; and in paragraph (4), by striking 2018 through 2022 and inserting 2023 through 2027 . Section 738A(b) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–1(b) ) is amended— in paragraph (1), by striking 2022 and inserting 2027 ; and in paragraph (5), by striking 2022 and inserting 2027 .
Connections2 off-index
2 references not yet in our index
- 21 USC 379j–1(a)
- 21 USC 379j–1(b)
Citation graph
cites case law
Sec. 204
Reauthorization; reporting requirement
Cite21 USC 379j–1(a)
Cite21 USC 379j–1(b)
Cites 2Cited by 0 across 0 sources